Instylla HES Hypervascular Tumor Pivotal Study

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional transarterial chemoembolization, while resulting in an acceptable risk of device and procedure-related serious adverse events.

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06170619` - Obsidio™ Conformable Embolic Registry
	Completed	`NCT04272216` - An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres

NCT number	NCT04523350
Study type	Interventional
Source	Instylla, Inc.
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 4, 2021
Completion date	September 30, 2024

Instylla HES Hypervascular Tumor Pivotal Study

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms